← Eichor
Condition: Chronic Phase Ph Chronic Myeloid Leukemia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Chronic Phase Ph Chronic Myeloid Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Phase 2 · 24 location(s) · Novartis Pharmaceuticals · NCT07354074Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML
Phase N/A · 2 location(s) · Il-Yang Pharm. Co., Ltd. · NCT06665412ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
Phase 1 · 4 location(s) · Marlise Luskin, MD · NCT03595917Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03589729Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03263572Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML
Phase 1/Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06757855ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid L
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05007873A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chr
Phase N/A · 54 location(s) · Novartis Pharmaceuticals · NCT07549516Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resis
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT01746836A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Phase 3 · 18 location(s) · Il-Yang Pharm. Co., Ltd. · NCT03459534Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Phase 1 · 9 location(s) · Ascentage Pharma Group Inc. · NCT04260022Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Phase 1/Phase 2 · 39 location(s) · Novartis Pharmaceuticals · NCT04925479A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Ph
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT06401603
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.